Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
CALL
Unity
U
$20B
| $3.52M | ﹤0.01% |
79,800
+29,800
| +60% | +$1.21M |
|
|
NIQ
2477
NIQ Global Intelligence PLC
NIQ
$4.98B
| $3.52M | ﹤0.01% |
213,467
+212,998
| +45,415% | +$3.12M |
|
2478
IDT Corp
IDT
$1.64B
| $3.51M | ﹤0.01% |
68,552
-23,125
| -25% | -$1.16M |
|
2479
Innospec
IOSP
$2.31B
| $3.51M | ﹤0.01% |
45,848
-493
| -1% | -$37.2K |
|
2480
Relay Therapeutics
RLAY
$4.34B
| $3.5M | ﹤0.01% |
414,143
-47,736
| -10% | -$341K |
|
2481
Ingevity
NGVT
$2.57B
| $3.5M | ﹤0.01% |
59,105
+4,220
| +8% | +$229K |
|
2482
First Majestic Silver
AG
$9.64B
| $3.5M | ﹤0.01% |
209,951
-1,173,452
| -85% | -$16.3M |
|
|
HI
2483
DELISTED
Hillenbrand
HI
| $3.49M | ﹤0.01% |
110,170
+10,673
| +11% | +$329K |
|
2484
Monro
MNRO
$346M
| $3.49M | ﹤0.01% |
174,235
+7,499
| +4% | +$138K |
|
2485
National Bank Holdings
NBHC
$1.93B
| $3.49M | ﹤0.01% |
91,844
+21,531
| +31% | +$811K |
|
2486
The GEO Group
GEO
$4.06B
| $3.48M | ﹤0.01% |
216,176
-58,012
| -21% | -$967K |
|
2487
Coty
COTY
$2.44B
| $3.48M | ﹤0.01% |
1,130,139
-287,658
| -20% | -$1.05M |
|
2488
Ducommun
DCO
$3.04B
| $3.48M | ﹤0.01% |
36,588
+2,594
| +8% | +$242K |
|
2489
Kodiak Sciences
KOD
$2.4B
| $3.48M | ﹤0.01% |
124,334
+55,485
| +81% | +$1.14M |
|
|
HTO
2490
H2O America
HTO
$2.66B
| $3.46M | ﹤0.01% |
70,565
+7,861
| +13% | +$377K |
|
2491
Northwest Bancshares
NWBI
$2.31B
| $3.45M | ﹤0.01% |
287,451
+60,756
| +27% | +$739K |
|
2492
Capricor Therapeutics
CAPR
$393M
| $3.45M | ﹤0.01% |
119,372
+64,279
| +117% | +$839K |
|
2493
Interface
TILE
$2.22B
| $3.43M | ﹤0.01% |
122,921
+8,057
| +7% | +$220K |
|
2494
Teladoc Health
TDOC
$1.26B
| $3.43M | ﹤0.01% |
489,982
-48
| -0% | -$376 |
|
2495
OR Royalties Inc
OR
$6.23B
| $3.42M | ﹤0.01% |
96,706
+6,576
| +7% | +$230K |
|
2496
Quaker Houghton
KWR
$2.93B
| $3.42M | ﹤0.01% |
24,898
+1,601
| +7% | +$216K |
|
|
KKR.PRD
2497
KKR & Co 6.25% Series D Preferred Stock
KKR.PRD
$2.54B
| $3.42M | ﹤0.01% |
65,893
-43,987
| -40% | -$2.23M |
|
2498
CALL
AdvisorShares Pure US Cannabis ETF
MSOS
$936M
| $3.41M | ﹤0.01% |
+722,900
| New | +$3.22M |
|
2499
Northwest Natural Holdings
NWN
$2.14B
| $3.41M | ﹤0.01% |
72,868
+6,046
| +9% | +$282K |
|
2500
Azenta
AZTA
$1.48B
| $3.41M | ﹤0.01% |
102,398
-54,335
| -35% | -$1.78M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.